nature portfolio

Corresponding author(s):	Francisco Bezanilla
Last updated by author(s):	Jun 30, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

़ .	トつ	Ť.	C	H٦.	\sim
٠,	LЪ	H.	ISI	ш	LO

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
\times	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

We used a in-house developed acquisition software, GPatchMC64.exe (Ver. 1.1)

Data analysis

We used a in-house developed analysis software, Analysis.exe (Ver. 2.0), to measure, fit and integrate the current traces, Excel (version 2208), Graphpad Prism 9, MATLAB (R2020b) to plot and fit the curves, ChimeraX (1.2.5), VMD to analyze the structural data, Snapgene (Version 7.0) to align the sequences.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data generated and resources used in this study will be made available to readers upon request. The reason that we did not choose to deposit all the raw data acquired directly is that the electrophysiological data is in our own format that would require a long processing to make it into standard format, such as ascii. On the

· ·		e of the data we can perform the format change for the specific data of interest. s studies can be accessed in protein data bank, NavPas PDB: 6A95; Nav1.7 M11 PDB: 7XVF; Nav1.5 PDB: 6UZ3			
The protein structure	es analyzed in thi	sacutes can be accessed in protein data bank. Navi as 1 bb. 0A33, Navi. 7 Mili 1 bb. 7/Wi , Navi. 3 1 bb. 0023			
Research inv	olving hu	man participants, their data, or biological material			
		vith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> thnicity and racism.			
Reporting on sex	and gender	NA			
Reporting on race, ethnicity, or other socially relevant groupings		NA			
Population chara	cteristics	NA			
Recruitment		NA			
Ethics oversight		NA			
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.			
Field-spe	ecific re	porting			
Please select the o	ne below that is	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences	В	ehavioural & social sciences			
For a reference copy of t	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scier	nces stu	udy design			
All studies must dis	sclose on these	points even when the disclosure is negative.			
Sample size		calculation was performed. We follow the standards in the field to include at least 4 independent measurements of any given perimental protocol.			
Data exclusions	Oocytes with hi	Oocytes with high leak current or low expression were excluded from analysis.			
Replication	Oocytes from different batches were used to replicate the results and in all cases the results are well replicated. All the mutants and experimental protocols were repeated in at least 4 different oocytes from at least 2 different batches.				
Randomization	All the oocytes were selected randomly for mRNA injection and the injected oocytes in good health were selected randomly for recordings.				
Blinding	We did not utilize double blind experimental design because the phenotypically, the differences among the mutants and the wild type are big. And the analysis was done systematically.				
Reportin	σ for sr	pecific materials, systems and methods			
<u> </u>	<u> </u>	about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,			
'		your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & ex	perimental s	ystems Methods			
	Involved in the study n/a Involved in the study				
Antibodies		ChIP-seq			
Eukaryotic cell lines		Flow cytometry			
		ogy MRI-based neuroimaging			
Animals an					
Dual use research of concern					
✓ Plants					